Anne-Marie Li-Kwai-Cheung, MChem, MTOPRA, RAPS, is Senior Vice President, Development, Regulatory, and Quality at Neurvati Neurosciences and GRIN Therapeutics, responsible for the creation of robust product development and regulatory strategies and to oversee their execution to ensure registration of products across Neurvati affiliates.  She joined Neurvati in January 2025 bringing over 25 years of broad experience in the pharmaceutical industry.  Prior to Neurvati, she was Chief Development Officer at Wave Life Sciences overseeing preclinical and clinical drug development activities having originally joined Wave in February 2022 as the SVP, Regulatory Affairs, Compliance, and Policy.  Prior to that, she spent 8 years at Roche in Basel, Switzerland, where she started in Global Regulatory Affairs and went on to hold leadership positions of increasing levels of responsibility in global drug development and global program leadership within the neurology and rare disease therapeutic areas. She served as Life Cycle Leader for tominersen in Huntington’s disease, guiding the Phase 3 program and other late-stage development activities, including responsibility for commercial activity, reimbursement, medical affairs, development and manufacturing and supply. In addition, she led the filing and development team at Roche through the global launch of Ocrevus for multiple sclerosis.  Prior to her work at Roche, Anne-Marie was at Genzyme, leading regulatory filings, including a filing team for an advanced therapy during a period of significant legislative changes.

Anne-Marie received her undergraduate and master’s degrees in chemistry at the University of Salford, UK.